Survival-time statistics for sample space reducing stochastic processes.

Phys Rev E

School of Physical & Mathematical Sciences, Central University of Haryana, Mahendergarh 123 029, India.

Published: April 2016

Stochastic processes wherein the size of the state space is changing as a function of time offer models for the emergence of scale-invariant features observed in complex systems. I consider such a sample-space reducing (SSR) stochastic process that results in a random sequence of strictly decreasing integers {x(t)},0≤t≤τ, with boundary conditions x(0)=N and x(τ) = 1. This model is shown to be exactly solvable: P_{N}(τ), the probability that the process survives for time τ is analytically evaluated. In the limit of large N, the asymptotic form of this probability distribution is Gaussian, with mean and variance both varying logarithmically with system size: 〈τ〉∼lnN and σ_{τ}^{2}∼lnN. Correspondence can be made between survival-time statistics in the SSR process and record statistics of independent and identically distributed random variables.

Download full-text PDF

Source
http://dx.doi.org/10.1103/PhysRevE.93.042131DOI Listing

Publication Analysis

Top Keywords

survival-time statistics
8
stochastic processes
8
statistics sample
4
sample space
4
space reducing
4
reducing stochastic
4
processes stochastic
4
processes size
4
size state
4
state space
4

Similar Publications

Introduction: Hypertension is among the most significant non-communicable public health issues worldwide. High blood pressure, or hypertension, has been associated with severe health consequences, including death, aneurysms, stroke, chronic renal disease, eye damage, heart attack, heart failure, peripheral artery disease, and vascular dementia. Consequently, this study aimed to investigate the predictors linked to survival time and the progression of blood pressure measurements in hypertensive patients.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Department of Neurology, LMU University Hospital, LMU Munich, Munich, Germany.

Background: Lewy body pathology (LBP) is common in autosomal dominant (ADAD) or sporadic Alzheimer disease (sAD). LBP seems to be the most frequent co-pathology in sAD and even in the relatively young ADAD population, where other co-pathologies are rare. Knowledge of neuropathological distribution patterns of LBP and associated survival and genetic characteristics in both AD variants is incomplete.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

University of Florida, College of Public Health and Health Professions and College of Medicine, Gainesville, FL, USA.

Background: The restricted mean disease progression (RMDP) is a measure of disease progression from baseline to a pre-specified follow-up visit. The RMST is a new statistical tool for survival analysis that is increasingly used in clinical trials. The RMST can be easily interpreted as the average survival time of patients from baseline to the pre-specified follow-up time.

View Article and Find Full Text PDF

Background: Subjective cognitive decline (SCD) is recognized to be in the Alzheimer's disease (AD) cognitive continuum. An international working group known as the SCD-initiative recently proposed "SCD plus" features, including report of memory problems, recent SCD relative to conversion, SCD over age 60, and consistent SCD over time, that increase the risk for future objective cognitive decline. These have not been fully assessed in a large community-based setting.

View Article and Find Full Text PDF

Clinical Manifestations.

Alzheimers Dement

December 2024

Department of Developmental and Educational Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain.

Background: The importance of coincidence of cognitive complaints between participants without objective impairment and their informants in predicting progression remains unclear (Nosheny et al, 2022). Our objective was to determine whether agreement in dyadic reporting at baseline can predict survival time to progression to MCI or dementia.

Method: A sample of 145 participants from the CompAS Study was included in a survival analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!